105 related articles for article (PubMed ID: 28552935)
1. Optimal strategy in chemotherapy for Malthusian model of cancer growth.
Maroński R
Acta Bioeng Biomech; 2017; 19(1):63-68. PubMed ID: 28552935
[TBL] [Abstract][Full Text] [Related]
2. Optimal strategy in chemotherapy for a Gompertzian model of cancer growth.
Maroński R
Acta Bioeng Biomech; 2008; 10(2):81-4. PubMed ID: 19032003
[TBL] [Abstract][Full Text] [Related]
3. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
Ledzewicz U; Maurer H; Schättler H
Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
[TBL] [Abstract][Full Text] [Related]
4. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
Schättler H; Ledzewicz U; Cardwell B
Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
[TBL] [Abstract][Full Text] [Related]
5. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
Poleszczuk J; Bodnar M; Foryś U
Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
[TBL] [Abstract][Full Text] [Related]
6. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
Ledzewicz U; Schättler H
Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
[TBL] [Abstract][Full Text] [Related]
7. Drug scheduling of cancer chemotherapy based on natural actor-critic approach.
Ahn I; Park J
Biosystems; 2011 Nov; 106(2-3):121-9. PubMed ID: 21839140
[TBL] [Abstract][Full Text] [Related]
8. Modeling recombinant immunotoxin efficacies in solid tumors.
Chen KC; Kim J; Li X; Lee B
Ann Biomed Eng; 2008 Mar; 36(3):486-512. PubMed ID: 18183487
[TBL] [Abstract][Full Text] [Related]
9. A novel evolutionary drug scheduling model in cancer chemotherapy.
Liang Y; Leung KS; Mok TS
IEEE Trans Inf Technol Biomed; 2006 Apr; 10(2):237-45. PubMed ID: 16617612
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling of cyclic treatments of chronic myeloid leukemia.
Komarova NL
Math Biosci Eng; 2011 Apr; 8(2):289-306. PubMed ID: 21631131
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin dosing in children: calculation by different formulae.
Würthwein G; Krefeld B; Gerss J; Boos J
Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
[TBL] [Abstract][Full Text] [Related]
12. A microenvironment based model of antimitotic therapy of Gompertzian tumor growth.
Kozusko F; Bourdeau M; Bajzer Z; Dingli D
Bull Math Biol; 2007 Jul; 69(5):1691-708. PubMed ID: 17577604
[TBL] [Abstract][Full Text] [Related]
13. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.
Sinek J; Frieboes H; Zheng X; Cristini V
Biomed Microdevices; 2004 Dec; 6(4):297-309. PubMed ID: 15548877
[TBL] [Abstract][Full Text] [Related]
14. Drug kinetics and drug resistance in optimal chemotherapy.
Costa MI; Boldrini JL; Bassanezi RC
Math Biosci; 1995 Feb; 125(2):191-209. PubMed ID: 7881194
[TBL] [Abstract][Full Text] [Related]
15. Optimal robust control of drug delivery in cancer chemotherapy: a comparison between three control approaches.
Moradi H; Vossoughi G; Salarieh H
Comput Methods Programs Biomed; 2013 Oct; 112(1):69-83. PubMed ID: 23891423
[TBL] [Abstract][Full Text] [Related]
16. Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
Ling H; Samarasinghe S; Kulasiri D
Biosystems; 2013 Feb; 111(2):71-82. PubMed ID: 23254306
[TBL] [Abstract][Full Text] [Related]
17. Determination of an optimal control strategy for drug administration in tumor treatment using multi-objective optimization differential evolution.
Lobato FS; Machado VS; Steffen V
Comput Methods Programs Biomed; 2016 Jul; 131():51-61. PubMed ID: 27265048
[TBL] [Abstract][Full Text] [Related]
18. Numerical optimal control of a size-structured PDE model for metastatic cancer treatment.
Liu J; Wang XS
Math Biosci; 2019 Aug; 314():28-42. PubMed ID: 31176704
[TBL] [Abstract][Full Text] [Related]
19. Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development.
Chassagnole C; Jackson RC; Hussain N; Bashir L; Derow C; Savin J; Fell DA
Biosystems; 2006; 83(2-3):91-7. PubMed ID: 16236428
[TBL] [Abstract][Full Text] [Related]
20. Optimal control oriented to therapy for a free-boundary tumor growth model.
Calzada MC; Fernández-Cara E; Marín M
J Theor Biol; 2013 May; 325():1-11. PubMed ID: 23485361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
